Stockscreener 앱 받기
10.55
2.73%
0.28
시간 외 거래:
10.55
전일 마감가:
$10.27
열려 있는:
$10.41
하루 거래량:
33,187
Relative Volume:
0.28
시가총액:
$654.34M
수익:
-
순이익/손실:
$-159.39M
주가수익비율:
-
EPS:
-
순현금흐름:
$-105.22M
1주 성능:
-1.31%
1개월 성능:
+7.87%
6개월 성능:
-27.44%
1년 성능:
+4.46%
1일 변동 폭
$10.25
$11.02
1주일 범위
$10.21
$11.02
52주 변동 폭
$8.75
$17.02
Abivax Adr Stock (ABVX) Company Profile
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-14 | 개시 | Leerink Partners | Outperform |
| 2023-11-14 | 개시 | Morgan Stanley | Equal-Weight |
Abivax Adr 주식(ABVX)의 최신 뉴스
Check Out Abivax ADR (ABVX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Insider’s View: Deciphering Abivax ADR (ABVX)’s Financial Health Through Ratios - The Dwinnex
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewswire Inc.
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - MSN
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032 - GlobeNewswire Inc.
Abivax SA Advances with Positive Trial OutcomesTipRanks.com - TipRanks
Abivax SA Announces Upcoming General MeetingTipRanks.com - TipRanks
Guggenheim starts Abivax stock with Buy, cites promising ulcerative colitis drug By Investing.com - Investing.com
Abivax SA Secures Funding and Expands Operations - TipRanks
Citi Appointed as Depositary Bank for Abivax SA's ADR Program - Business Wire
Abivax Adr (ABVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.11%
0.50%
자본화:
|
볼륨(24시간):